Lorpiprazole

This classification denotes an antipsychotic agent with the molecular formula C21H26F3N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M14O7T47Q, chemically known as (- )-cis-5,5a,6,7,8,8a-hexahydro-3-(2-(4-(alpha,alpha,alpha-trifluoro-m-tolyl)-1-piperazinyl)ethyl)cyclopenta(3,4)pyrrolo(2,1-c)-s-triazole but generally known as lorpiprazole, which bears US NIH Compound Identifier 3045380. European Medicines Agency schedules Lorpiprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08590MIG. The term LORPIPRAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). LORPIPRAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lorpiprazole under HS 29335995 and SITC 51576. As of Q4 2014, LORPIPRAZOLE remains the US FDA Preferred Term for this commodity. Lorpiprazole bears US NLM identifiers UMLS ID C2825691 and NCI Concept Code C81579. SMILES: FC(F)(F)C1CC(N2CCN(CCC3N4CC5C(CCC5)C4NN3)CC2)CCC1.